Published in Gynecol Oncol on February 26, 2013
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol (2014) 2.19
Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev (2015) 0.92
DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol (2014) 0.87
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol (2015) 0.86
Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort. Hum Reprod (2013) 0.86
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst (2015) 0.83
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol (2016) 0.82
Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery. Fam Cancer (2016) 0.80
Cigarette smoking and endometrial carcinoma risk: the role of effect modification and tumor heterogeneity. Cancer Causes Control (2014) 0.79
Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. Gynecol Oncol (2015) 0.76
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol (2015) 0.76
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst (2017) 0.76
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol (2015) 0.75
Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. Cancer Causes Control (2017) 0.75
Symposium on advances in endometrial cancer epidemiology and biology. Gynecol Oncol (2015) 0.75
Adjuvant therapy in early-stage endometrial cancer: a systematic review of the evidence, guidelines, and clinical practice in the U.S. Oncologist (2014) 0.75
An update of the classical Bokhman's dualistic model of endometrial cancer. Prz Menopauzalny (2016) 0.75
Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer (2016) 0.75
Features of omental adipose tissue in endometrial cancer patients with 'standard' or 'metabolically healthy' obesity: associations with tumor process characteristics. Springerplus (2016) 0.75
Associations of Dietary Long-Chain ω-3 Polyunsaturated Fatty Acids and Fish Consumption With Endometrial Cancer Risk in the Black Women's Health Study. Am J Epidemiol (2016) 0.75
The sL1CAM in sera of patients with endometrial and ovarian cancers. Arch Gynecol Obstet (2016) 0.75
Features of endometrial cancer in patients with 'metabolically healthy' versus 'standard' obesity: the decreasing frequency of metabolically healthy obesity. Future Sci OA (2015) 0.75
Bokhman's dualistic model of endometrial carcinoma. Revisited. Gynecol Oncol (2013) 0.75
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol (2016) 0.75
Risk of cardiovascular disease among women with endometrial cancer compared to cancer-free women in the Women's Health Initiative. Cancer Epidemiol (2017) 0.75
Endometrial Cancer Trends by Race and Histology in the USA: Projecting the Number of New Cases from 2015 to 2040. J Racial Ethn Health Disparities (2016) 0.75
A comparison of statistical methods for the study of etiologic heterogeneity. Stat Med (2017) 0.75
Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee. J Gynecol Oncol (2017) 0.75
Two pathogenetic types of endometrial carcinoma. Gynecol Oncol (1983) 6.26
Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol (2011) 2.57
FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol (2009) 2.34
Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring) (2006) 2.17
Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol (2000) 2.16
Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.75
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol (2003) 1.72
Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol (2007) 1.65
Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol (1995) 1.64
Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer (2003) 1.57
Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol (1994) 1.55
Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control (2010) 1.52
Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol (2009) 1.49
Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer (2007) 1.43
Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol (2011) 1.42
Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control (2009) 1.35
Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev (2008) 1.30
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol (2009) 1.29
Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat (2006) 1.29
Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol (1998) 1.21
Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev (2005) 1.19
Trends in endometrial cancer incidence rates in the United States, 1999-2006. J Womens Health (Larchmt) (2011) 1.17
Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial/ethnic population of women. J Nutr (2006) 1.15
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer (2012) 1.14
Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol (1997) 1.14
Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol (2012) 1.10
Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst (2004) 1.10
Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.04
What can we learn about disease etiology from case-case analyses? Lessons from breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.01
BRCA germline mutations in women with uterine serous carcinoma--still a debate. Int J Gynecol Cancer (2010) 1.01
Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol (2008) 1.00
Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol (2003) 0.95
Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch (2010) 0.92
Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. Anticancer Res (2007) 0.90
Active and passive cigarette smoking and the risk of endometrial cancer in Poland. Eur J Cancer (2009) 0.87
Nonendometrioid endometrial carcinomas. Semin Diagn Pathol (2010) 0.87
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat (2007) 0.86
Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res (2000) 0.86
Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer (2011) 0.86
Pregnancy history and risk of endometrial cancer. Epidemiology (2011) 0.85
Current concepts in the pathology and epigenetics of endometrial carcinoma. Pathology (2010) 0.83
Association between uterine serous carcinoma and breast cancer. Gynecol Oncol (2004) 0.83
Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol (2006) 0.82
Racial and ethnic variations in the incidence of cancers of the uterine corpus, United States, 2001-2003. J Womens Health (Larchmt) (2009) 0.81
The impact of BMI on subgroups of uterine cancer. Br J Cancer (2009) 0.81
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev (2004) 5.32
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002) 4.39
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res (2006) 4.26
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 3.50
Metacognitive awareness and prevention of relapse in depression: empirical evidence. J Consult Clin Psychol (2002) 3.49
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 3.39
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2005) 2.94
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.82
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst (2008) 2.72
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer (2006) 2.68
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer (2004) 2.46
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res (2006) 2.33
Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,. Rev Panam Salud Publica (2004) 2.33
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 2.32
Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer (2006) 2.31
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol (2007) 2.27
Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2002) 2.24
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol (2007) 2.17
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol (2012) 2.13
Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol (2008) 2.08
Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.08
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol (2012) 2.07
High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer (2007) 2.06
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2010) 1.99
Endometrial dye instillation: a novel approach to histopathologic evaluation of morcellated hysterectomy specimens. J Minim Invasive Gynecol (2013) 1.96
Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol (2007) 1.94
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 1.92
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst (2002) 1.83
A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res (2010) 1.82
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
History of the FIGO cancer staging system. Int J Gynaecol Obstet (2008) 1.81
Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer (2014) 1.80
Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst (2012) 1.80
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol (2011) 1.80
A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev (2003) 1.80
Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol (2007) 1.79
Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet (2002) 1.78
Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev (2004) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol (2011) 1.72
Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer (2013) 1.71
Stability of archived liquid-based cervical cytologic specimens. Cancer (2003) 1.70
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol (2007) 1.70
Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res (2012) 1.68
Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol (2012) 1.67
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol (2009) 1.67
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer (2009) 1.65
Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 1.65
Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol (2008) 1.65
Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol (2009) 1.62
Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol (2007) 1.60
Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis (2002) 1.58
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (2011) 1.57
Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev (2004) 1.56
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review. Gynecol Oncol (2006) 1.56
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol (2013) 1.54
A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol (2007) 1.53